People
-
University of Melbourne spin-off Otifex has reportedly raised $1.1 million for the development of a nasal spray to treat otitis media with effusion (OTE), in which viscous fluid builds up in the middle ear, potentially… Read more . . .
-
Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company “to pursue other business ventures.” Asmacure is developing an inhaled nictonic receptor agonist,… Read more . . .
-
Activaero has hired Christian Pangratz as its new Chief Business Officer, replacing Henrik Luessen. Pangratz comes to Activaero from Nektar, where he served as Executive Director of Business Development. Luessen will continue to work with… Read more . . .
-
Chuck Bramlage has been appointed President and Chief Executive Officer of Pearl Therapeutics, replacing interim President and CEO Howard Rosen. Pearl, a California pharmaceutical company developing inhaled treatments for COPD and asthma, was founded in… Read more . . .
-
Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine… Read more . . .
-
CMO PharmaForm, a wholly-owned subsidiary of Akela Pharma, has hired J. Blair West, formerly of Bend Research and Azo Pharma, as Vice President of Pharmaceutical Operations. In addition, the company says, Feng Zhang will become… Read more . . .
-
Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson’s disease. The assets Civitas has licensed from Alkermes include a pipeline,… Read more . . .
-
Patrick G. LePore, President, CEO, and Chair of Par Pharmaceuticals will temporarily take over the reins at the company’s subsidiary Strativa Pharmaceuticals after Strativa’s President John A. MacPhee resigned. MacPhee was also Executive VP of… Read more . . .
-
The Defense Advanced Research Projects Agency (DARPA) has awarded a $5.7 million grant to Pulmatrix for development of inhaled cationic airway lining modulator (iCALM) products to protect military personnel and civilians against airborne diseases. Read… Read more . . .
-
William M. Wells has resigned as Chairman of the Board of Valeant Pharmaceuticals and has been replaced by Robert A. Ingram. Valeant subsidiary Biovail is co-devloping the Staccato loxapine inhaler with Alexza Pharmaceuticals. The FDA… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland